Yuviwel Gains 7-Year U.S. Orphan Drug Exclusivity for Ascendis Pharma
ASND sits 84% above its 52-week low of $124.06.
Summary
Ascendis Pharma has secured Orphan Drug Exclusivity (ODE) from the FDA for its drug Yuviwel (navepegritide), a treatment for achondroplasia. This designation grants Ascendis Pharma U.S. marketing exclusivity for Yuviwel through February 2033. The company also announced that Yuviwel is now commercially available in the U.S. This 7-year exclusivity period is a significant positive development, protecting the drug from generic competition and securing a key revenue stream for a rare genetic disorder treatment. This regulatory milestone enhances the drug's commercial potential and strengthens Ascendis Pharma's market position in the long term. Investors will watch for initial sales figures and market adoption of Yuviwel.
At the time of this announcement, ASND was trading at $228.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.1B. The 52-week trading range was $124.06 to $248.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.